SCHEMBL503133

SCHEMBL503133

N[C@@H](Cn1ncnn1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 5/20 0.41
GRIA2 P42262 5/20 0.41
GRIA4 P48058 5/20 0.41
GRIK5 Q16478 2/20 0.41
SLC1A3 P43003 1/20 0.40
LTA4H P09960 1/20 0.38
KMO O15229 1/20 0.36
GRIA3 P42263 3/20 0.35
TYR P14679 1/20 0.35
DOHH Q9BU89 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PTGS1 P23219 1/20 0.34
SLC7A11 Q9UPY5 1/20 0.34
HSD17B10 Q99714 2/20 0.34
CYP1A2 P05177 2/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15208985 1.00 GRIA1 (0.41) GRIA1GRIA2GRIA4GRIK5SLC1A3
SCHEMBL21299181 1.00 GRIA1 (0.41) GRIA1GRIA2GRIA4GRIK5SLC1A3
SCHEMBL5828104 0.76 GRIA1 (0.45) GRIA1GRIA2GRIA4GRIK5SLC1A3
SCHEMBL8562681 0.71 SLC7A5 (0.38) GRIA1GRIA2GRIA4GRIK5SLC1A3
SCHEMBL8562687 0.71 SLC7A5 (0.38) GRIA1GRIA2GRIA4GRIK5SLC1A3
SCHEMBL333082 0.68
SCHEMBL15804707 0.67 SLC7A5 (0.54) SLC1A3TYRKDM4EPTGS1HSD17B10
SCHEMBL6395050 0.67 FOLH1 (0.55) SLC1A3TYRDOHHKDM4E
SCHEMBL503194 0.67 EGLN3 (0.50) GRIA1GRIA2GRIA4GRIK5KMT2A
SCHEMBL941137 0.67 EGLN3 (0.50) GRIA1GRIA2GRIA4GRIK5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247858-A1 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2020-08-06 US claimed
EP-3678683-A2 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF Fog Pharmaceuticals, Inc. (US) 2020-07-15 EP claimed
CN-111372942-A β -catenin function modulating agents and methods thereof 弗格制药有限公司 2020-07-03 CN claimed
WO-2019051327-A2 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2019-03-14 WO claimed
EP-3335720-A1 C-DI-GMP BINDING PEPTIDES Universität Basel (CH) 2018-06-20 EP claimed
US-6939967-B2 Non-proteinogenic L-amino acids Consortium für elektrochemische Industrie GmbH (DE) 2005-09-06 US claimed
US-20040197879-A1 Process for producing non-proteinogenic L-amino acids by fermentation CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH 2004-10-07 US claimed
EP-1191106-B1 Process for the fermentative preparation of non-proteinogenic L-amino acids CONSORTIUM ELEKTROCHEM IND (DE) 2004-04-28 EP claimed
US-20020039767-A1 Process for producing non-proteinogenic L-amino acids by fermentation CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH 2002-04-04 US claimed
CN-117377651-B Cationic lipid with side chain containing functional groups and application thereof 厦门赛诺邦格生物科技股份有限公司 2025-04-01 CN disclosed
US-20250034080-A1 CATIONIC LIPID CONTAINING SIDE-CHAIN FUNCTIONAL GROUPS AND APPLICATION THEREOF XIAMEN SINOPEG BIOTECH CO., LTD. (CN) 2025-01-30 US disclosed
EP-4458805-A1 CATIONIC LIPID CONTAINING FUNCTIONAL GROUP ON SIDE CHAIN, AND USE THEREOF Xiamen Sinopeg Biotech Co., Ltd. (CN) 2024-11-06 EP disclosed
CN-117377651-A Cationic lipid with side chain containing functional groups and application thereof 厦门赛诺邦格生物科技股份有限公司 2024-01-09 CN disclosed
US-11834482-B2 Agents modulating beta-catenin functions and methods thereof FOG PHARMACEUTICALS, INC. (US) 2023-12-05 US disclosed
US-7015331-B2 Non-proteinogenic L-amino acids Consortium für elektrochemische Industrie GmbH (DE) 2006-03-21 US disclosed
US-20050222426-A1 Non-proteinogenic L-amino acids CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH 2005-10-06 US disclosed
US-6939967-B2 Non-proteinogenic L-amino acids Consortium für elektrochemische Industrie GmbH (DE) 2005-09-06 US disclosed
US-20040197879-A1 Process for producing non-proteinogenic L-amino acids by fermentation CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH 2004-10-07 US disclosed
US-6756216-B2 BATCH PROCESSING USING NUCLEOPHILIC COMPOUND Consortium für elektrochemische Industrie GmbH (DE) 2004-06-29 US disclosed
US-20020039767-A1 Process for producing non-proteinogenic L-amino acids by fermentation CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH 2002-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222426-A1 Non-proteinogenic L-amino acids BCAT2, BCAT1, CBS GRIA1 2816/4885GRIA2 2599/4885GRIA4 2767/4885
US-20020039767-A1 Process for producing non-proteinogenic L-amino acids by fermentation CBS, BCAT2, BCAT1 GRIA1 3536/4885GRIA2 3393/4885GRIA4 3285/4885
US-20200247858-A1 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF CTNNB1, CTNNBL1, CTNNA1 GRIA1 4249/4885GRIA2 4470/4885GRIA4 4405/4885
US-20250034080-A1 CATIONIC LIPID CONTAINING SIDE-CHAIN FUNCTIONAL GROUPS AND APPLICATION THEREOF PHOSPHO1, LIPA, SLC7A1 GRIA1 717/4885GRIA2 1120/4885GRIA4 1202/4885
US-11834482-B2 Agents modulating beta-catenin functions and methods thereof CTNNB1, CTNNBL1, CTNNA1 GRIA1 4249/4885GRIA2 4470/4885GRIA4 4405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.